

Cyclin Dependent Kinase 2 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/C4EF7BED63FCEN.html>

Date: November 2020

Pages: 95

Price: US\$ 3,500.00 (Single User License)

ID: C4EF7BED63FCEN

Abstracts

Cyclin Dependent Kinase 2 - Pipeline Review, H2 2020

SUMMARY

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Cyclin-dependent kinase 2 is an enzyme encoded by the CDK2 gene. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex which regulates progression through the cell cycle. Activity of CDK2 is especially critical during the G1 to S phase transition. CDK2 associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B).

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 1, 2, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Immunology, Ear Nose Throat Disorders, Metabolic Disorders and Respiratory which include indications Breast Cancer, Coronavirus Disease 2019 (COVID-19), Lung Cancer, Metastatic Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Inflammation, Non-Small Cell Lung Cancer, Peritoneal Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Astrocytoma, Colon Cancer, Cystic Fibrosis, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Gliosarcoma, Hearing Disorders, High-Grade Glioma, Laryngeal Cancer, Lymphoma, Mantle Cell Lymphoma, Metastatic

Brain Tumor, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Pediatric Diffuse Intrinsic Pontine Glioma, Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis, Small-Cell Lung Cancer, Thymic Carcinoma and Uterine Cancer.

The latest report Cyclin Dependent Kinase 2 - Pipeline Review, H2 2020, outlays comprehensive information on the Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)

The report reviews Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects

The report assesses Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's

most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Overview

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Companies Involved in Therapeutics Development

Adastra Pharmaceuticals Inc

Apollo Therapeutics LLC

Arc Therapeutics Inc

Astex Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

Neosome Life Sciences LLC

Nuvation Bio Inc

Pfizer Inc

Prous Institute for Biomedical Research SA

Rizen (Suzhou) Biosciences Co Ltd

Shanghai Junshi Bioscience Co Ltd

Tiziana Life Sciences Plc

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Drug Profiles

AT-7519 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-68127 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
ebvaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fadraciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
kenpaullone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEOS-518 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUV-422 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

PF-07104091 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapacitabine + seliciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seliciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zotiraciclib citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Dormant Products

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Discontinued Products

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Product Development Milestones

Featured News & Press Releases

Oct 26, 2020: Cyclacel presents phase 1 clinical data showing safety, anti-tumor activity and good oral bioavailability of fadraciclib in patients with advanced solid tumors at the EORTC-NCI-AACR Symposium 2020

Oct 13, 2020: Nuvation Bio announces FDA acceptance of investigational new drug (IND) application for NUV-422 for treatment of patients with high-grade gliomas

Oct 06, 2020: ICR to study fadraciclib to treat paediatric neuroblastoma

Sep 21, 2020: Cyclacel announces Fadraciclib abstract selected for oral presentation in the Late Breaking and Best Proffered Paper session at the 32nd EORTC-NCI-AACR Symposium 2020

Aug 21, 2020: Tiziana granted a patent on the use of milciclib in combination with tyrosine kinase inhibitors for treatment of hepatocellular carcinoma and other cancers

Jul 13, 2020: Cyclacel's clinical stage CDK2/9 inhibitor Fadraciclib targets key anti-apoptotic and oncogenic pathways in cancer

May 14, 2020: Tiziana Lifesciences announces online publication of two abstracts at the American Society of Clinical Oncology (ASCO) reporting clinical activity and safety of Milciclib in patients with advanced hepatocellular carcinoma

May 11, 2020: Tiziana Life Sciences announces publishing of two e-abstracts featuring its Miliciclib

Dec 09, 2019: Cyclacel's CYC065 and Venetoclax demonstrate therapeutic potential and anticancer activity in acute myeloid and chronic lymphocytic leukemias

Nov 06, 2019: Cyclacel Pharmaceuticals announces multiple clinical abstracts on CYC065 selected for presentation at the ASH 2019 Annual Meeting

Sep 09, 2019: Cyclacel Pharmaceuticals announces first patient treated with oral CYC065 in a phase 1 study in patients with advanced solid tumors

Sep 04, 2019: Tiziana Life Sciences -phase 2a clinical data

Sep 04, 2019: Adastra Pharmaceuticals to present at the 2019 Janney Healthcare Conference

Jul 24, 2019: Tiziana reveals positive results for Milciclib in liver cancer trial

Jul 22, 2019: Tiziana reports phase 2a clinical data with milciclib monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Products under Development by Companies, H2 2020 (Contd..3), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Aadastra Pharmaceuticals Inc, H2 2020
Pipeline by Apollo Therapeutics LLC, H2 2020
Pipeline by Arc Therapeutics Inc, H2 2020
Pipeline by Astex Pharmaceuticals Inc, H2 2020
Pipeline by Cyclacel Pharmaceuticals Inc, H2 2020
Pipeline by Neosome Life Sciences LLC, H2 2020
Pipeline by Nuvation Bio Inc, H2 2020
Pipeline by Pfizer Inc, H2 2020
Pipeline by Prous Institute for Biomedical Research SA, H2 2020
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H2 2020
Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2020
Pipeline by Tiziana Life Sciences Plc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

I would like to order

Product name: Cyclin Dependent Kinase 2 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/C4EF7BED63FCEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C4EF7BED63FCEN.html>